Development
Traws Pharma, Inc.
TRAW
$1.50
-$0.025-1.65%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 226.00K | 226.00K | 226.00K | 226.00K | 226.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 226.00K | 226.00K | 226.00K | 226.00K | 226.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 226.00K | 226.00K | 226.00K | 226.00K | 226.00K |
| SG&A Expenses | 9.03M | 8.45M | 8.37M | 8.45M | 8.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.80M | 22.35M | 21.86M | 19.85M | 17.88M |
| Operating Income | -21.57M | -22.12M | -21.63M | -19.63M | -17.66M |
| Income Before Tax | -20.18M | -20.84M | -20.62M | -18.96M | -17.31M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.18 | -20.84 | -20.62 | -18.96 | -17.31 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.18M | -20.84M | -20.62M | -18.96M | -17.31M |
| EBIT | -21.57M | -22.12M | -21.63M | -19.63M | -17.66M |
| EBITDA | -21.55M | -22.11M | -21.62M | -19.61M | -17.64M |
| EPS Basic | -0.96 | -1.00 | -0.99 | -0.91 | -0.83 |
| Normalized Basic EPS | -0.60 | -0.62 | -0.62 | -0.57 | -0.52 |
| EPS Diluted | -0.97 | -1.00 | -0.99 | -0.91 | -0.83 |
| Normalized Diluted EPS | -0.60 | -0.62 | -0.62 | -0.57 | -0.52 |
| Average Basic Shares Outstanding | 83.87M | 83.78M | 83.71M | 83.65M | 83.66M |
| Average Diluted Shares Outstanding | 83.87M | 83.78M | 83.71M | 83.65M | 83.66M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |